Skip to main content
SHAANXI KANGHUI PHARMACEUTICAL CO., LTD logo

SHAANXI KANGHUI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 603139 ISIN · CNE100002XT3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 940 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603139

About SHAANXI KANGHUI PHARMACEUTICAL CO., LTD

http://www.sxkh.com/

Shaanxi Kanghui Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company focuses on modernizing traditional Chinese medicine while also manufacturing chemical drugs and health-related products. Its therapeutic portfolio primarily addresses cardiovascular and cerebrovascular diseases, respiratory conditions, and gynecological health. By integrating advanced pharmaceutical technologies with traditional medicinal knowledge, the company provides treatment solutions across various dosage forms, including capsules, tablets, and granules. Its operations encompass the entire value chain from raw material sourcing and extraction to final product formulation and marketing, emphasizing quality control and innovation in drug delivery systems.

Recent filings

Filing Released Lang Actions
康惠股份关于持股5%以上股东部分股份解除质押及再质押的公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement regarding the pledge and re-pledge of shares by a >5% shareholder. It is not a financial report (e.g., Annual or Interim Report), not an earnings release, not a proxy or dividend notice, and does not fall into specialized categories like M&A, board changes, or ESG. It is a general regulatory disclosure of shareholder pledge activity, so it defaults to Regulatory Filings (RNS).
2026-05-28 Chinese
康惠股份2026年限制性股票激励计划（草案）
Remuneration Information Classification · 85% confidence The document is a detailed equity incentive plan (“限制性股票激励计划”) drafted by the company for its directors, senior management, and core employees. It specifies grant amounts, vesting conditions, performance targets, adjustment mechanisms, accounting treatment, and corporate approval procedures. This is not a general governance code, proxy notice, or annual/interim report but a compensation scheme. Under the provided filing taxonomy, it best fits “Remuneration Information” (code DEF 14A) which covers detailed executive and director compensation disclosures such as equity incentive plans.
2026-05-27 Chinese
康惠股份董事会薪酬与考核委员会关于公司2026年限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 78% confidence The document is a formal opinion issued by the company’s Board Remuneration and Assessment Committee regarding the legality and compliance of a proposed 2026 restricted stock incentive plan. It does not present financial results, changes in management, dividends, or detailed compensation tables, nor is it announcing publication of another report. Instead, it is a compliance/regulatory announcement that does not fit other specific categories, making it a general regulatory filing.
2026-05-27 Chinese
康惠股份第六届董事会第十一次会议决议公告
Regulatory Filings Classification · 46% confidence The document is a public announcement of the board of directors meeting resolutions (approval of the 2026 restricted stock incentive plan and related authorization to the board), but it does not report changes in board membership/management, does not provide proxy materials, financial statements, or ESG data. It is a corporate regulatory announcement that does not fit into a more specific category. Therefore, it is classified under the general regulatory filings fallback category.
2026-05-27 Chinese
康惠股份2026年限制性股票激励计划授予激励对象名单
Share Issue/Capital Change Classification · 87% confidence The document is a formal announcement of the allocation of newly issued restricted shares under the company’s 2026 equity incentive plan, detailing the amounts granted to directors, senior management, and employees. This constitutes a change in the company’s capital/share structure by issuing shares. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-27 Chinese
康惠股份2026年限制性股票激励计划（草案）摘要公告
Share Issue/Capital Change Classification · 85% confidence The document is a formal announcement of the company’s 2026 restricted stock incentive plan (equity incentive), detailing the issuance of new shares (799.04 million shares) to employees and management, pricing, vesting conditions, and procedures. It is not a financial report, management change notice, or a link to a report, but rather a share issuance/capital change filing. Under our taxonomy, this falls under Share Issue/Capital Change (SHA).
2026-05-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.